GlassScriptPhysician profile
Deandra L Smith
NPI 1144926676
$8,128.33
in general payments reported to CMS, 2019-2025
16 companies · $3,782 in 2025
The $3,782 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,241 · 2024: $3,106 · 2025: $3,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,116 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,116.18 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,548.18 | 2023-2025 | Invega Sustenna |
| Alkermes, INC. | $1,330.41 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $853.20 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $836.65 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $642.91 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $628.01 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $537.97 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $525.31 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $422.19 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $406.05 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $153.56 | 2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $99.66 | 2023-2025 | Rexulti |
| Biogen, INC. | $48.54 | 2024-2025 | Zurzuvae |
| Corium, LLC | $44.31 | 2023-2024 | Azstarys |
| Indivior INC. | $31.10 | 2023-2024 | Perseris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $20.28 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deandra Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.